C3 BioC3 Bio

Confidential 18.04.23

Combating diseases with small molecule Combating diseases with small molecule compoundscompounds

C3C3BIO BIO GmbHGmbH

C3 BioC3 Bio

Confidential18.04.23

Company concept: Company concept: rational drug designrational drug design

Patents and exclusive world licenses on Patents and exclusive world licenses on families of compounds (purines and families of compounds (purines and pyrazolopyrimidines)pyrazolopyrimidines)

Extensive network of cooperation partners Extensive network of cooperation partners

Progress made in 3 indication areas: Progress made in 3 indication areas: Rheumatoid arthritis, restenosis and cancerRheumatoid arthritis, restenosis and cancer

C3 BioC3 Bio

Confidential18.04.23

PyrazolopyrimidinesPyrazolopyrimidines

RoscovitineRoscovitine

N

N

NNH

NH

NH

NH2

1407

C3 BioC3 Bio

CancerCancer

Recognized hallmarks of cancersRecognized hallmarks of cancers Uncontrolled proliferationUncontrolled proliferation Evasion of apoptosisEvasion of apoptosis Sustained angiogenesisSustained angiogenesis Genomic instabilityGenomic instability

Common target: cyclin-dependent kinases Common target: cyclin-dependent kinases (CDKs)(CDKs)

Confidential 18.04.23

C3 BioC3 Bio

CancerCancer

Identified compounds have iIdentified compounds have increasedncreased:: AActivity in biochemical and cellular assaysctivity in biochemical and cellular assays PPotency in vivootency in vivo Metabolic stabilityMetabolic stability

Tumour cell migration as well as endothelial Tumour cell migration as well as endothelial migration are specifically being investigated migration are specifically being investigated to prevent cancer metastasis-a number of to prevent cancer metastasis-a number of compounds show promising resultscompounds show promising results

Confidential 18.04.23

C3 BioC3 Bio

Confidential18.04.23

RestenosisRestenosis

Focus is on identification of new drug Focus is on identification of new drug candidates interfering with vascular smooth candidates interfering with vascular smooth muscle cells (VSMC) proliferationmuscle cells (VSMC) proliferation

Identified compounds may be useful for anti-Identified compounds may be useful for anti-restenotic therapy-some of the work is restenotic therapy-some of the work is published published

C3 BioC3 Bio

Confidential18.04.23

Rheumatoid ArthritisRheumatoid Arthritis

Concentrate on the 30-40% non-Concentrate on the 30-40% non-responding RA patientsresponding RA patients

New targets-neutrophils and synovial New targets-neutrophils and synovial fibroblastsfibroblasts

Patients at early stage of disease Patients at early stage of disease progressionprogression

C3 BioC3 Bio

Confidential18.04.23

Rheumatoid Arthritis: Rheumatoid Arthritis: LGR1407 induces LGR1407 induces neutrophil apoptosisneutrophil apoptosis

0

20

40

60

80

100

120

0 0.01 0.1 1 10 50 100

Ap

op

toti

c ce

lls

(%)

LGR1407

R-roscovitine

Concentration (M)

C3 BioC3 Bio

Confidential18.04.23

Rheumatoid Arthritis: Rheumatoid Arthritis: LGR1407 inhibits LGR1407 inhibits TNF-induced secretion of IL-8 in TNF-induced secretion of IL-8 in neutrophilsneutrophils

C3 BioC3 Bio

Confidential18.04.23

Rheumatoid Arthritis: Rheumatoid Arthritis: LGR1407 inhibits LGR1407 inhibits proliferation of synovial fibroblasts from proliferation of synovial fibroblasts from RA patientsRA patients

0

20

40

60

80

100

120

control 0.1uM 0.5uM 1.0uM 5.0uM 10uMPro

life

ration

(%

co

ntr

ol)

LGR 1407 concentration

C3 BioC3 Bio 18.04.23

Rheumatoid ArthritisRheumatoid Arthritis

Molecular target had been identifiedMolecular target had been identified

Compounds are orally availableCompounds are orally available

Toxicology and pharmacokinetic studies indicate a Toxicology and pharmacokinetic studies indicate a useful therapeutic windowuseful therapeutic window

in vivo studies successfully carried outin vivo studies successfully carried out

C3 BioC3 Bio

Confidential18.04.23

Combating diseases with small molecule Combating diseases with small molecule compoundscompounds

For more information contactFor more information contact

Dr. Paul Pechan, CEODr. Paul Pechan, CEO

Email:ppechan@compuserve.comEmail:ppechan@compuserve.com

Tel: 49 89 67847951Tel: 49 89 67847951